Sequence-Specific Biosensors Report Drug-Induced Changes in Epigenetic Silencing in Living Cells by Huang, Xudong et al.
ORIGINAL RESEARCH ARTICLE
Sequence-Specific Biosensors Report Drug-Induced
Changes in Epigenetic Silencing in Living Cells
Xudong Huang,1 Rammohan Narayanaswamy,1 Kathleen Fenn,1 Sebastian Szpakowski,1
Clarence Sasaki,2 Jose Costa,1 Pilar Blancafort,3 and Paul M. Lizardi1
Treatment with demethylating drugs can induce demethylation and reactivation of abnormally silenced tumor
suppressor genes in cancer cells, but it can also induce potentially deleterious loss of methylation of repetitive
elements. To enable the observation of unwanted drug effects related to loss of methylation of repetitive DNA,
we have developed a novel biosensor capable of reporting changes in DNA accessibility via luminescence, in
living cells. The biosensor design comprises two independent modules, each with a polydactyl zinc finger
domain fused to a half intein and to a split-luciferase domain that can be joined by conditional protein splicing
after binding to adjacent DNA targets. We show that an artificial zinc finger design specifically targeting DNA
sequences near the promoter region of the L1PA2 subfamily of Line-1 retroelements is able to generate lumi-
nescent signals, reporting loss of epigenetic silencing and increased DNA accessibility of retroelements in human
cells treated with the demethylating drugs decitabine or 5-azacytidine.
Introduction
Demethylating drugs are being increasingly utilized incancer therapeutics. These drugs are relatively non-
specific, and their actions are known to involve complex ef-
fects on transcriptional programs that go far beyond their
action on gene targets of interest. It has been established that
the demethylating activity is accompanied by a complex re-
sponse involving downregulation and activation of a large
number genes (Gius et al., 2004; Hagemann et al., 2011). Re-
cently it was demonstrated that the demethylating drugs
azacytidine and decitabine (both drugs are in clinical use and
in several ongoing clinical trials) can dramatically alter the
expression of the cMet ongogene in a number of different
cancer cell lines. The abnormal expression of the cMet gene
under the influence of either of the drugs is driven by an
alternative promoter, and results in an alternatively spliced
transcript (Weber et al., 2010). This abnormal cMet transcript
had also been observed in tumor tissues of patients with
bladder cancer (Wolff et al., 2010). In both cases the alterna-
tive promoter driving abnormal transcription is a Line-PA2
retroelement sequence of primate origin (Lizardi, 2010),
which becomes active under the demethylating action of the
drugs, or in the case of bladder cancers is demethylated
during the course of tumor evolution. Therefore, an impor-
tant problem in human epigenetics is to attain a better
mechanistic understanding of the abnormal pharmacological
activation of promoters derived from the ubiquitous retro-
element sequences in the human genome. While it is well
established that silencing of retroelements during gameto-
genesis is based on homology-driven mechanism involving
piRNAs (Halic and Moazed, 2009; Moazed, 2009), the
mechanisms responsible for maintenance of silencing in so-
matic cells remain to be elucidated in detail.
Powerful, sequencing-based methods are available to
measure genome-wide changes in chromatin states, includ-
ing transcription factor binding, histone modifications, or
DNA methylation (Park, 2009; Hawkins et al., 2010). How-
ever, there are few approaches that enable observation of
locus-specific epigenetic changes by imaging living cells or
tissues. The success in monitoring the expression of genes
involved in photoperiod processes via luminescence, in real
time, over several days of observation, has set the stage for
the use of similar approaches for the study of chromatin
remodeling. Artificial fluorescent or luminescent fusion
proteins introduced in the genomes of model organisms can
be used to address this need, however, these powerful ap-
proaches are not applicable to human tissue experimentation
due to ethical issues. Thus, there is an emerging need for a
new class of nonintegrating biosensors specifically designed
for imaging applications in human tissues, and for enabling
time-resolved observation of specific epigenetic alterations in
living cells.
To begin addressing this emerging need, we identified as an
attractive biological model the abnormal loss of epigenetic si-
lencing of retroelements under the influence of pharmacological
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agents. Long interspersed nuclear elements belonging to the
Line-1 family of repeats represent a large fraction of the human
genome (Lander et al., 2001), and a small subset of these elements
remain transpositionally active. During normal gametogenesis,
silencing of retrotransposon sequences by DNA methylation is
established under the direction of piRNAs and the Piwi family of
proteins (Aravin et al., 2008; Kuramochi-Miyagawa et al., 2008).
The first observations of widespread Line-1 retrotransposon
expression were reported for adult testicular tumors (Bratthauer
and Fanning, 1992) and for pediatric germ cell tumors (Brat-
thauer and Fanning, 1993). More recently, the loss of epigenetic
silencing of Line-1 elements has been reported in a multiplicity
of cancers (e.g., Schulz et al., 2006; Belancio et al., 2009), and in the
context of environmental exposures to chemicals and other
toxicants. Notably, the loss of methylation of Line-1 elements,
and the activation of the Line-1 antisense promoter can be in-
duced by drugs (Weber et al., 2010) or by inflammatory cyto-
kines, such as Interleukin-6 (Gasche et al., 2011), and these
epigenetic changes can be observed after a few days in cell
culture. It would be of considerable interest to be able to observe
the abnormal loss of methylation of Line-1 elements, and the
resulting increase in DNA accessibility, in living cells or tissues,
as inflammatory processes evolve over time, or during disease
progression or different drug treatments. Here we describe a
proof-of-concept for the experimental use of a new class of
nonintegrating, sequence-specific biosensors specifically de-
signed for imaging applications in human cells and tissues, and
for enabling direct observation of the time course of retroelement
chromatin remodeling.
Materials and Methods
Selection of the zinc finger target sites on L1PA2
The L1PA2 5¢UTR promoter region was analyzed by se-
lecting, from the total 4600 L1PA2 sequences (obtained from
Human Genome Build 16 using RepeatMasker), a subset of
2230 sequences that contained an intact 5¢-UTR. These 2230
sequences were aligned, using CLUSTALX, to generate a
consensus sequence of the 912 base L1PA2 5¢-UTR (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertonline.com/dna). The consensus was used for
selection of a pair of pentadactyl zinc finger 15 bp target sites
using the Zinc Finger Tools program (www.scripps.edu/
mb/bar bas/zfdesign/zfdesignhome.php). The sequence
was analyzed on either the same strand or on the opposite
strand. The candidate sites containing ANN and TNN trip-
lets were excluded as these have been empirically shown to
be less specific relative to GNN or CNN triplets. The two
target sites for zinc finger-1 (ZF1) and zinc finger-2 (ZF2)
were selected based on their high scores as determined by
the program, close distance in between and relative high
allele frequencies of more than 1000 copies in the human
genome. The target site sequences are: CCTGACCCCC
GAGCA (1) and GACCCACTTGAGGAG (2), which are
separated by 7 bp in the consensus sequence.
Cloning of the L1PA2-targeting zinc fingers
ZF1 and ZF2
The two zinc finger constructs (Supplementary Figs. S2 and
S3) were assembled using the Zinc Finger Tools program
(www.scripps.edu/mb/barbas/zfdesign/zfdesignhome.php)
and cloned into the bacterial pMAL-c4 · expression vector
using assembly polymerase chain reaction (PCR) as previously
described (Beltran et al., 2007). Each construct contains a N-
terminal Maltose binding protein (Mbp) tag and a fusion of five
zinc finger domains of 549 amino acid residues in length.
Bacterial expression of the ZF1 and ZF2
The plasmids were transformed into XL1-blue cells,
grown in 5 mL TB media at 37C over night, and induced
37C with 1500 mM isopropyl-beta-D-1-thiogalactopyrano-
side (IPTG) for 3 h. Cells were harvested and resuspended
in 300 mL zinc finger binding assay (ZnBA) buffer contain-
ing 10 mM Tris, pH 7.5, 90 mM KCl, 1 mM MgCl2, 90 mM
ZnCl2, and 5 mM DTT. Cells were lysed by freeze/thaw in
dry ice/ethanol bath and the supernatants were collected
and stored at - 80C until use. Zinc finger protein expres-
sion was analyzed by Western blot using the mouse anti-
Mbp antibody (Sigma-Aldrich, St. Louis, MO).
Zinc finger-DNA binding ELISA
The biotinylated DNA target hairpin oligos (Supplemen-
tary Table S1) harboring ZF1 and ZF2 target sites were ob-
tained from Integrated DNA Technologies (IDT, Coralville,
IA). The DNA oligos were resuspended in ZnBA buffer to
1mg/mL. Flat bottom 96-well plates were coated with 0.4 mg
streptavidin (Pierce, Rockford, IL) per well in 100 mL car-
bonate buffer at 4C overnight. After washing two times
with water, 100mL 4.0 ng/mL DNA oligo was added to each
well in ZnBA buffer and incubated 37C for 1 h. The wells
were then washed with water and blocked with 200mL 3%
bovine serum albumin in ZnBA buffer for 1 h at 37C. Un-
purified bacterial expression lysate (100mL) was added in
ZnBA buffer containing 1% BSA and 120 ng/mL salmon
sperm DNA and incubated for 1 h at room temperature. The
unpurified lysate with the empty vector was used as a con-
trol. After washing with water, 100 mL mouse anti-Mbp an-
tibody (Sigma-Aldrich) in ZnBA with 1% BSA was added
and incubated for 30 min at room temperature. After wash-
ing with water, 100mL alkaline phosphatase-conjugated goat
anti-mouse antibody (Sigma-Aldrich) in ZnBA with 1% BSA
was added and incubated for 30 min at room temperature.
After washing with water, the colorimetric ELISA was per-
formed by adding 100mL substrate pNPP solution and re-
actions were stopped after 3 h incubation with 50mL 2N
NaOH and the absorbance was measured at 405 nm with a
plate reader.
Cloning of the DNA-guided nano-assembly
biosensor constructs
The DNA-guided nano-assembly (DGnA) biosensor is a
two-module construct comprising module 1 and module 2
(Supplementary Figs. S4 and S5). Each module was assem-
bled using InFusion PCR kit (Clontech, Mountain View, CA)
from a L1PA2-targeting zinc finger domain as described
above and a half of the split intein-firefly luciderase fusion
domain, and were placed into separate mammalian expres-
sion vectors DNA4/HisMax (Invitrogen, Carlsbad, CA). The
domain organizations of each module is shown as the fol-
lowing: Module 1: ZF1_NLuc_NInt; Module 2: ZF2_CInt_
CLuc. Both modules were His- and NLS-tagged at the
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N-termini. The original split intein-luciferase fusion con-
structs (NLuc_NInt and CInt_CLuc) were kind gifts from Dr.
Edmund Schwartz and Dr. Tom Muir from the Rockefeller
University.
Cell culture, transfection, and drug treatments
Human HeLa cells (ATCC, Manassas, VA) were grown in
Eagle’s minimum essential medium (ATCC) with 10% heat-
inactivated fetal bovine serum (Sigma-Aldrich) in plastic six-
well tissue culture plates at 37C in a humidified atmosphere
containing 5% CO2. Transfection efficiency using Effectene
(Invitrogen) and Fugene (Roche, Basel, Switzerland) was
evaluated using replicate experiments involving transfection
with 750 ng of plasmid DNA. Using real-time quantitative
PCR, we estimate an average of 2000 internalized molecules
per nucleus. By extrapolation, 600 ng of artificial target
plasmid would result in internalization of *1600 molecules/
nucleus, while 1200 ng of artificial target plasmid would re-
sult in internalization of *3200 molecules/nucleus. These
numbers of internalized plasmid molecules are consistent
with the published literature, where transfection of HeLa
cells with lipofectamine has been quantified by Glover et al.
(2010) using real-time PCR, yielding results similar to ours.
Since the copy number of L1PA2 repetitive elements in the
human genome is *4600 (or 9200 in a diploid genome),
these experimental estimates of transfection efficiency indi-
cate that we can internalize artificial plasmid DNA targets in
HeLa cells (as performed to generate the data in Fig. 2c) in
numbers representing roughly one-third of the number of
L1PA2 elements in the genome.
To measure the DGnA biosensor response to epigenetic
drug treatments, different concentrations of fresh 5-aza-2-
deoxycytidine (Sigma-Aldrich) or 5-aza-cytidine (Sigma-
Aldrich) were added to the cells every 24 h through change
of medium. The drug treatments were maintained before and
after the biosensor transfection throughout the desired pro-
tocol. No artificial DNA targets were used in these experi-
ments. One day before biosensor transfection, 2.0 · 105 cells
were seeded in 2 mL growth medium per well. Next day the
plasmids of 100 ng module 1 and 50 ng module 2 were
transfected using the transfection reagent FugeneHD (Roche)
according to manufacturer’s instructions. 10 ng Renilla lucif-
erase plasmid pRL-TK (Promega, Madison, WI) was co-
transfected as a control for transfection efficiency. After 20 h
post-transfection growth, cells were harvested with ice cold
PBS buffer and cell pellets were lysed in 40mL 1 · passive
lysis buffer (Promega) containing 1 · protease inhibitors
(Roche, Madison, WI) and analyzed for protein expression
and Luciferase activity.
Western blot analysis of the DGnA biosensor
expression and Luciferase assay
For Western blot analysis, cell lysates were mixed with the
same volume of 2 · Laemmli sample buffer, boiled, and
loaded onto 10% polyacrylamide gels containing sodium
dodecyl sulfate. Proteins were transferred to polyvinylidene
fluoride membranes ImmobilonFL (Millipore, Billerica,
MA). We used a mouse anti-His antibody (Sigma-Aldrich)
and a goat anti-mouse secondary antibody IRdye800CW (LI-
COR, Lincoln, NE). The protein bands were visualized and
quantitated using the Odyssey Infrared Imaging System (LI-
COR). The protein marker of the Smart His-tagged Protein
Standard (GenScript, Piscataway, NJ) was used as a refer-
ence for quantitation. For luciferase assay, cell lysates was
analyzed using the dual-luciferase reporter assay kit ac-
cording to the manufacturer’s instruction (Promega) and the
luminescence was read using a luminometer GloMax-20/20
(Promega).
L1PA2 DNA methylation assay
Genomic DNA samples were isolated from drug-treated
and control HeLa cells using a DNA isolation kit for blood
and cells (Qiagen, Valencia, CA). The primers used for
L1PA2 bisulfate-PCR is: TTTTATTAGGGAGTGTTAGA
TAGTGGG and ACCCACTTAAAAAAACAATCTACCC.
DNA methylation was measured by bisulfite-PCR, followed
by mass spectrometry-based MassARRAY analysis using the
Sequenom EpiTyper analysis platform at the Yale Center for
Genome Analysis.
Results
Polydactyl zinc finger (PZF) proteins bind double-stranded
DNA based on sequence-specific molecular recognition of
DNA bases by helical peptide domains, which penetrate the
major groove of B-DNA (Klug, 2010). Each PZF recognizes
3 bp of DNA in a quasi-modular manner, and thereby the
rational design of artificial PZFs is possible (Blancafort et al.,
2004; Bhakta and Segal, 2010). Just as the PCR achieves sin-
gle-locus specificity based on the use of two different prim-
ers, it is possible to target a genomic locus with high
specificity employing a set of two contiguous five-finger PZF
modules, which together recognize 15 + 15 = 30 bp. The use of
separate modules of PZF proteins to recognize specific DNA
sequences, resulting in the assembly of a green fluorescent
protein reporter has been described (Stains et al., 2006; Fur-
man et al., 2009). We modified this system to be under the
control of a conditional protein splicing system, in which
fragments of an artificially split Saccharomyces cerevisiae vac-
uolar membrane ATPase (VMA) intein complement through
rapamycin-induced heterodimerization of the FK506 binding
protein (FKBP) and FKB12-Rapamycin binding domain of
mTor (FBR) Proteins (Mootz and Muir, 2002). This intein-
based biosensor system was able to report the presence of the
drug rapamycin in a living animal, in real time (Schwartz
et al., 2006) meeting one of our key design requirements.
In our biosensor design, specific DGnA of a luminescent
reporter is driven by two independent protein fusions each
comprising a PZF module with five PZF domains, a half-
intein domain, and a half-luciferase-enzyme domain. Figure
1a illustrates the two zinc finger biosensor structures ZF1
and ZF2, and the resulting DGnA process, in which each of
the modules specifically binds at adjacent sites in the ge-
nome, followed by intein-catalyzed splicing and the gener-
ation of covalently joined and active luciferase. We targeted
specific DNA sequences representing the consensus sequence
(see Supplementary Fig. S1) of the 5¢-UTR of Line-1 elements
belonging to the L1PA2 subfamily, a group of sequences that
numbers *4600 interspersed copies, originating in Homi-
noidea, and largely absent in older species of monkeys such
as Rhesus macaque. To evaluate DNA-recognition specificity,
we expressed the artificial zinc finger proteins in Escherichia
coli (Fig. 1c), and confirmed by means of ELISA assays that
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each of the two PZF modules specifically binds to its cognate
sequence, and not to other DNA sequences (Fig. 1b, d). Note
that the two strongest binding signals in Figure 1d corre-
spond to the perfect L1PA2 genomic target sequences Tg1wt
and Tg2wt.
We then showed that each of the two fusion proteins
could be expressed in HeLa cells (Fig. 2a), and optimized
protein expression levels by adjusting the amount of trans-
fected DNA until an expression level ranging between 56,000
and 134,000 molecules per cell (Fig. 2b) was attained for each
of the protein modules. The feasibility of the DGnA process
was evaluated by co-transfecting HeLa cells with an artificial
DNA plasmid that harbors the entire target region corre-
sponding to the L1PA2 consensus sequence. As shown in
Figure 2c, transfection was performed with different
amounts of target DNA or with an irrelevant DNA target,
and biosensor performance was assessed as a ratio of firefly
luciferase (biosensor) to Renilla luciferase (transfection con-
trol) in a dual luciferase assay. The results, as indicated by
increasing values for the luminescence ratio of firefly lucif-
erase to Renilla luciferase, are consistent with the two ge-
netically encoded biosensor modules being able to bind the
artificial L1PA2 sequence (denominated Tg2xAB) in the
transfected targets, and undergoing conditional protein
splicing to generate, via the DGnA process, molecules of
covalently joined and active luciferase. We also observed a
significant amount of luminescence signal for the empty
(target-free) vector DNA input measurement, most likely
arising from background (nonconditional) intein splicing as
reported by others (Schwart et al., 2006) that can occur in the
absence of DNA binding. Since the largest input used in this
experiment (1200 ng of transfected plasmid) has been deter-
mined to correspond to *3200 molecules of artificial target
internalized in cell nuclei (see Materials and Methods
FIG. 1. The two-module design of the DGnA biosensor and characterization of DNA binding of the zinc finger protein in
each module. (a) schematic diagram showing His- and NLS-tagged module 1 (ZF1_NLuc_NInt) and module 2
(ZF2_CInt_CLuc). Each module contains a pentadactyl zinc finger domain linked with one half of the split VMA intein and a
split firefly luciferase fusion domain. Binding of both modules via their respective zinc finger domains to their specific L1PA2
target sites induces intein-mediated protein splicing. This reaction results in covalent reconstitution of a functional luciferase
capable of generating luminescence in the presence of luciferin. NLS, nuclear localization signal. ZF1 and ZF2, zinc finger
domain 1 and 2. NLuc and NInt, N-terminal half of the firefly lucifease and VMA intein fusion domain. CLuc and CInt, C-
terminal half of the VMA intein and firefly fusion domain. (b) DNA target sequences used to evaluate artificial zinc finger
binding. Underlined bases represent changes from L1PA2 consensus sequence. (c) Immunoblot analysis of Mbp-tagged zinc
finger domains in bacterial lysates following IPTG induction. (d) ELISA analysis of bacterially expressed zinc finger protein
binding to the wild-type and mutant DNA targets. Bacterial lysates containing expressed zinc finger domains were used
without further purification (see Materials and Methods section), and the control lysate was generated by an empty vector
expressing only the Mbp protein. Tg, target; wt, wild-type; mt, mutant; DGnA, DNA-guided nano-assembly; VMA, vacuolar
membrane ATPase; Mbp, maltose binding protein; IPTG, isopropyl-beta-D-1-thiogalactopyranoside.
BIOSENSORS REPORT CHANGES IN EPIGENETIC SILENCING S-5
section), and this number of artificial targets is smaller than
the number of L1PA2 elements in a diploid genome, it seems
unlikely that background signal could be generated by a
small subcomponent of undermethylated L1PA2 genomic
DNA. Despite the nonconditional intein splicing background
issue, the experiment shown in Figure 2c demonstrates a
strong luminescence response in the presence of artificial
DNA targets.
To demonstrate the utility of the genetically encoded
biosensors in a relevant biological context we performed
several experiments where cells are exposed to drugs capa-
ble of inducing DNA demethylation. The responses of
mammalian cells to the demethylating drugs decitabine
and 5-azacitidine have been extensively documented in the
literature. To illustrate the effects of decitabine on the DNA
methylation levels of L1PA2 repetitive elements in HeLa
cells, in which Line-1 elements have been reported to be
predominantly methylated (Teneng et al., 2011), we treated a
HeLa cell culture with decitabine, at a concentration of
2.5 mM, for a period of 4 or 5 days. The drug induced a loss of
methylation corresponding to values lower than 70% of the
control HeLa cell culture methylation levels in 8 out of 21
CpG dinucleotides. The lowest observed levels of relative
DNA methylation compared to controls, after decitabine
treatment, were 51%, 54%, and 55% for three of the 21 CpG
dinucleotides assayed (Table 1). The drug concentrations
used in these and subsequent experiments were chosen to be
roughly comparable to the maximum concentrations (Cmax)
FIG. 2. Luciferase activity of the DGnA biosensor in response to specific target DNA transfected into HeLa cells. (a)
Immunoblot analysis of the His-tagged modules 1 and 2 of the biosensor expressed in HeLa cells. The empty vector is the
expression vector pcDNA4/HisMax without biosensor inserts. HeLa cells transfected with empty vector (second lane) show
several bands, probably representing cross-reactivity of the anti-His antibody with cellular proteins. Cells transfected with
expression vectors harboring each of the two biosensor constructs show additional bands corresponding to the expected
molecular weights for Module 1 (95.8 kd) and Module 2 (36.1 kd). (b) Quantitation of the protein expression of the two
modules in transfected HeLa cells using a Western blot analyzed in a LiCOR instrument. The 50 kDa band with the known
protein amount (15 ng) of the Smart His-tagged Protein Standard (SS) was used as the reference. (c) Measurement of
luminescence in HeLa cells transiently transfected with the two modules of the biosensor along with increasing amounts of
co-transfected target DNA. Firefly luciferase luminescent signal was normalized by Renilla luciferase luminescent signal as
the transfection control. Tg2xAB, a puc19 vector carrying target DNA, comprising two copies of the target 1 and 2 sequences,
separated by 2 bp.
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achieved in human plasma at clinically used dosages and
schedules of administration. Human plasma Cmax values
are 3 to 11 mM 5-azacytidine and 0.3 to 1.6 mM decitabine
(Marcucci et al., 2005; Blum et al., 2008; Cashen et al., 2008).
Similar drug concentrations to those used in our study have
been utilized in recent cell-line based studies of these drugs
(Hollenbach et al., 2010).
We performed an experiment, using triplicate cell cultures,
where the biosensors were transfected into HeLa cells 3 days
after the start of drug treatment. The results, shown in Figure
3a, demonstrate that incremental doses of decitabine lead to
significant increases in luminescent output of the DGnA
biosensors, demonstrating the ability of the system to report
changes in accessibility of the genomic DNA harboring
L1PA2 elements, as they become demethylated. We per-
formed a similar experiment using the demethylating drug 5-
azacytidine, and the results are shown in Figure 3b. In this
second experiment, also performed in triplicate, the DGnA
biosensors report the increased DNA accessibility in L1PA2
genomic DNA, resulting from 5-azacytidine treatment,
showing a drug concentration-dependent increase in relative
luminescent output.
Discussion
The potential for future imaging applications of zinc-
finger based biosensors is supported by the success of recent
efforts to image repetitive DNA elements using PZF fusions
coupled to Green Fluorescent protein (Lindhout et al., 2007,
2010). These simple fusions have enabled the detection of
centromere repeats in Arabidopsis thaliana and in mouse
cells. Our initial demonstration of the utility of the more
complex splicing-based DGnA biosensor technology illus-
trates some of the limitations of the system as currently
implemented using luciferase as a signal-generating moiety.
The signal to noise ratio is not yet high enough to enable the
detection of DNA accessibility changes at single-copy gene
loci. The major cause of noise in the system is the occur-
rence of background intein splicing in the absence of target
DNA. It might be possible to engineer modifications in the
structure of the intein to reduce the rate of the spontaneous
splicing reaction. Since the binding of the zinc finger mod-
ules to DNA is of very high affinity, the modified inteins
will linger long enough when bound to DNA to permit
splicing even when the engineered fragments have lower
affinity for each other. Other modifications that could en-
hance the performance of the system include the utilization
of natural or engineered luciferases with higher photon
yields.
As reported here, the Line-1PA2 epigenomic biosensor can
be used to monitor the cellular response to demethylating
drugs that modulate epigenetic states in chromatin. We
emphasize that the system is currently capable of reporting
changes in DNA accessibility, which may or may not reflect
changes in DNA methylation. Nonetheless, future improve-
ments in the molecular design of the biosensors could in-
volve incorporating modules with the capability of
recognizing methylated DNA. It has been reported that the
human zinc-finger proteins Kaiso, ZBTB4, and ZBTB38 can
bind methylated DNA in a sequence-specific manner (Sasai
et al., 2010). As we begin to more fully understand the mo-
lecular recognition contacts of Kaiso and Kaiso-like zinc
Table 1. Measurements of Line-1 5-UTR DNA Methylation in HeLa Cells Treated with 2.5 mM













I1PA2-1_CpG_1 0.28 0.23 0.20 0.82 0.72
I1PA2-1_CpG_4.5.6 0.47 0.41 0.39 0.87 0.83
I1PA2-1_CpG_7 0.54 0.63 0.48 1.16 0.89
I1PA2-1_CpG_8 0.16 0.17 0.19 1.06 1.23
I1PA2-1_CpG_9 0.54 0.63 0.48 1.16 0.89
I1PA2-1_CpG_10 0.61 0.42 0.36 0.69 0.59
I1PA2-1_CpG_12 0.54 0.63 0.48 1.16 0.89
I1PA2-1_CpG_13 0.39 0.32 0.26 0.82 0.67
I1PA2-1_CpG_14 0.71 0.51 0.57 0.72 0.80
I1PA2-1_CpG_15.16 0.59 0.40 0.40 0.68 0.67
I1PA2-1_CpG_17 0.44 0.37 0.27 0.84 0.63
I1PA2-1_CpG_18.19 0.53 0.45 0.37 0.85 0.69
I1PA2-1_CpG_21 0.44 0.44 0.32 1.00 0.72
I1PA2-1_CpG_22 0.43 0.36 0.31 0.82 0.72
I1PA2-1_CpG_23 0.62 0.57 0.34 0.92 0.55
I1PA2-1_CpG_25 0.42 0.37 0.30 0.87 0.71
I1PA2-1_CpG_26 0.26 0.21 0.19 0.80 0.71
I1PA2-1_CpG_28.29 0.36 0.32 0.28 0.90 0.79
I1PA2-1_CpG_30 0.26 0.21 0.19 0.80 0.71
I1PA2-1_CpG_31 0.28 0.32 0.14 1.12 0.51
I1PA2-1_CpG_33 0.32 0.22 0.17 0.69 0.54
DNA methylation was measured by bisulfite-polymerase chain reaction, followed by mass spectrometry analysis using the Sequenom
EpiTyper analysis platform. Data in the Ratio columns are presented as percentage of methylation at a given CpG site in the sequence
obtained from three separate experiments. The Ratio is the post-treatment methylation value divided by the value of the pretreated control.
Bold text indicates those ratios at or below 0.70.
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fingers, new possibilities will emerge for re-engineering
biosensors with more powerful recognition capabilities.
With a potentially more gentle system for recombinant
vector delivery, such as exosomes (Lakhal and Wood, 2011),
the biosensors could be used to measure drug responses in
epithelial cells from individual patients, or even in proxy
tissues derived from different individuals using iPS cell
technology. In this last application, the biosensors would
enable research in the individualized pharmacogenetics and
pharmacokinetics of demethylating drug responses. Notably,
it has been reported (Issa et al., 2005) as part of phase II clinical
trail studies with demethylating drugs, that there are marked
decreases in the methylation of Line-1 elements in patients
with leukemia undergoing treatment with decitabine. It
would be exciting if improved versions of the epigenomic
biosensors could be utilized to report on the status of Line-1
DNA accessibility in live blood cells derived from patients
undergoing treatment with demethylating drugs. It must be
emphasized that the DGnA technology is modular, and that
the biosensors can be readily modified to target other geno-
mic loci of interest through the use of appropriately modified
zinc finger modules. One could, for example, redesign the
two zinc finger modules of the biosensor to target other Line-
1 subfamilies, such as the human-specific Line-1HS elements.
Other retroelements, such as Alu, SVA, or HERV subfamilies
could also be specifically targeted. Different kinds of centro-
meric repeat sequences could be targeted to report on the
silencing status of specific centromere domains. A recent
publication reports that Satellite 2 demethylation induced by
5-azacytidine is associated with missegregation of chromo-
somes 1 and 2 in human somatic cells (Prada et al., 2012). The
ability to observe in living cells the loss of silencing of satellite
DNA in the context of demethylating drug treatment can
enable new experimental approaches for the study of drug-
induced genome instability.
The modularity of the biosensor can be extended to other
designs driving the assembly of split modules comprising a
variety of enzymes suitable for other imaging modalities.
Notably, a recent report described a molecularly engineered
split thymidine kinase reporter for imaging protein-protein
interactions with positron emission tomography (Massoud
et al., 2010), which enabled imaging in live animal models. In
the case of the DGnA system, thymidine kinase or any mo-
nomeric protein can in principle be split to generate inactive
fragments, and rejoined by splicing to generate active en-
zyme under the specific control of a genomic guide (target)
sequence. The flexibility in possible imaging modalities
should make the Line-1 biosensors we have described ex-
cellent tools to study the loss of silencing of these retro-
elements, possibly associated with Line-1 sense and
antisense promoter activation, in a variety of experimental
settings. We expect that DGnA biosensors will find many
applications in basic research, including systems biology,
and we also envision exciting possibilities in advanced
screens for discovery or improvement of epigenetic modu-
lation drugs. We also envision a novel and ambitious ther-
apeutic strategy, where an abnormal genome becomes a
drug target, and the DGnA process operates in the cell
nucleus as a factory of therapeutic proteins. For example, a
pro-apoptotic protein could be assembled via DGnA, upon
detection of DNA structural abnormalities (such as ERBB2 or
Myc amplification) or abnormal loss of epigenetic silencing of
Line-1 retroelement sequences.
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